AMITRIPTYLINE ( DrugBank: Amitriptyline )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
78下垂体前葉機能低下症1
97潰瘍性大腸炎1
226間質性膀胱炎(ハンナ型)2
299嚢胞性線維症4

78. 下垂体前葉機能低下症


臨床試験数 : 492 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00497562
(ClinicalTrials.gov)
May 20045/7/2007Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters)Exploratory Study to Investigate the Efficacy and Safety of Recombinant Growth Hormone as Add-on Treatment in Patients With Severe FibromialgiaFibromyalgia;Growth Hormone DeficiencyDrug: sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group);Drug: amitriptyline, fluoxetine and tramadol alone (control group)Centro Medico TeknonNULLCompleted18 YearsN/ABothPhase 2Spain

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003220-21-GB
(EUCTR)
26/02/202012/12/2019Management of diarrhoea in ulcerative colitis: multi-arm multi stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE.Management of diarrhoea in ulcerative colitis: multi-arm multi-stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE. - MODULATE Diarrhoea in patients with stable ulcerative colitis.
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856
MedDRA version: 20.1;Classification code 10033007;Term: Other ulcerative colitis;Classification code 10066557;Term: Chronic diarrhoea;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Amitriptyline
Product Name: Amitriptyline
INN or Proposed INN: Amitriptyline hydrochloride
Product Name: Ondansetron
INN or Proposed INN: Ondansetron hydrochloride dihydrate
Product Name: Loperamide
INN or Proposed INN: loperamide hydrochloride
University of LeedsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
491Phase 2;Phase 3United Kingdom

226. 間質性膀胱炎(ハンナ型)


臨床試験数 : 145 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05658874
(ClinicalTrials.gov)
December 1, 202223/11/2022A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic PainA Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic PainInterstitial CystitisDrug: Multimodal Bundle Drugs;Procedure: Operative Cystoscopy;Behavioral: Behavioral health consultation/therapy;Other: Pelvic floor physical therapy;Other: Usual Urogynecologic care;Drug: Bladder Instillation;Drug: Vaginal estrogen;Drug: Methenamine;Drug: Amitriptyline/GabapentinJocelyn FitzgeraldNULLRecruiting18 Years99 YearsFemale80Phase 3United States
2NCT00124306
(ClinicalTrials.gov)
February 200513/7/2005Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed PatientsBladder Diseases;Interstitial CystitisDrug: Amitriptyline;Other: PlaceboNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)University of PennsylvaniaCompleted18 YearsN/ABoth271Phase 3United States;Canada

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01309178
(ClinicalTrials.gov)
May 20094/3/2011Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and PlaceboAnti-inflammatory Pulmonal Therapy of CF Patients With Amitriptyline and Placebo - a Randomised, Double-blind, Placebo-controlled, Multicenter, Cohort - StudyCystic Fibrosis;PneumoniaDrug: Amitriptyline;Drug: ManniteUniversity Children’s Hospital TuebingenUniversität Duisburg-Essen;University of UlmRecruiting14 Years65 YearsBoth30Phase 2Germany
2EUCTR2006-002259-33-DE
(EUCTR)
10/10/200611/07/2006Protocol for a Phase II-studyAnti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blinded, placebo-controlled, cross over study -Protocol for a Phase II-studyAnti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blinded, placebo-controlled, cross over study - CF-patients develop a chronic pulmonary infection with Pseudomonas aeruginosa (P. aeruginosa). At present it is unknown why CF-patients are highly sensitive to P. aeruginosa infections and, most important, no curative treatment for cystic fibrosis is available. This Study should provide a novel anti-inflammatory treatment for cystic fibrosis, which reduces pulmonary complications, progression of the disease and may possibly increase the life-expectance of the patients.Trade Name: Amitriptylin-ct Tabletten
Product Name: Amitriptyline
INN or Proposed INN: AMITRIPTYLINE
Trade Name: Amitriptylin-ct Tabletten
Product Name: Amitriptyline
INN or Proposed INN: AMITRIPTYLINE
Trade Name: Amitriptylin-ct Tabletten
Product Name: Amitriptyline
INN or Proposed INN: AMITRIPTYLINE
Paediatrisches Sekretariat fuer Klinische StudienNULLNot RecruitingFemale: yes
Male: yes
18Phase 2Germany
3NCT00515229
(ClinicalTrials.gov)
October 20069/8/2007Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and PlaceboProtocol for a Phase II-Study Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo - Randomised, Double-Blinded, Placebo-Controlled, Cross Over - Study -Cystic Fibrosis;Infection;Pseudomonas AeruginosaDrug: amitriptylineUniversity Hospital TuebingenNULLCompleted18 Years50 YearsBoth18Phase 2Germany
4EUCTR2008-002673-13-DE
(EUCTR)
27/08/2008Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and PlaceboAnti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo Deficiency of the Cftr-molecule results in accumulation of ceramide in respiratory epithelial cells. Ceramide triggers a pro-inflammatory and -apoptotic status in cystic fibrosis patients. Amitriptyline reduces ceramide levels in the lung tissue, normalises the activity of cytokines and prevents constitutive cell death of epithelial cells. Amitriptyline prevents pulmonary infections of CF-mice with P. aeruginosa. Amitriptyline may result in an improved lung function of cystic fibrosis patients.Trade Name: Amitriptylin-CT
Product Name: Amitriptyline
INN or Proposed INN: Amitriptyline
PSKSNULLNot RecruitingFemale: yes
Male: yes
Phase 2Germany